Lyophilized formulations of tegavivint
US12208166B2 · kind B2 · utility
0Cited by
0References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 24, 2023 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Oct 24, 2043 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/26
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.